Online ISSN: 2515-8260

Keywords : end stage renal disease


Dermatological manifestations in patients with chronic kidney disease: A cross sectional study

Bindushree R, Priyashree R

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 2, Pages 373-379

Introduction: Chronic kidney disease (CKD) is associated with a complex array of cutaneous
manifestations caused either by the disease or by treatment. Cutaneous manifestations in chronic kidney
disease are polymorphic and diverse. Most patients with severe CKD progress to end stage renal disease
(ESRD) with significant morbidity and mortality. The Aim of our study was to evaluate the prevalence
and pattern of cutaneous disorders among patients with chronic kidney disease.
Materials and Methods: One hundred patients of chronic kidney disease above the age of 18 years with
dermatological manifestation were enrolled in the study. A detailed physical examination and
dermatological examination was done and findings recorded. Relevant investigations including complete
haemogram, diabetic profile, ANA, renal function tests, Liver function tests, electrolytes, viral markers,
serum calcium, phosphorous and PTH (parathormone) levels, KOH mount, culture & sensitivity, woods
lamp examination, biopsy was done if indicated.
Results: In our study we included 100 patients of CKD with cutaneous manifestations. The most
common cause of CKD in our study was found to be diabetic nephropathy which was seen in 47% (n=47)
patients. Pruritus was the most common dermatological manifestation seen in 73% (n=73) of the total
study population followed by xerosis in 68% (n=68). More than 50% of the study population had more
than one dermatological manifestations. Nail and hair changes was seen in 43% and 58% respectively.
Conclusion: Patients with end stage renal disease (ESRD) may present with variety of skin abnormalities
and the most common being pruritus and xerosis as seen in our study. An inter-disciplinary approach
involving dermatologists and nephrologists is essential to improve the quality of life of patients with
ESRD.

Effect of Hemodialysis on pulmonary function in patients with End stage renal disease

Shailendra Mane, C Bhujbal, Rajashri Mane, Rajesh Khayalappa

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 9774-9782

Background: The intermittent hemodialysis (IHD) has been a useful renal replacement
therapy for critically ill patients.Pulmonary dysfunction in end-stage kidney disease has
been seen as a straight effect of circulating uremic toxins or a secondary effect of
volume overload, anemia, immune suppression, premature airway closure, ventilationperfusion
mismatching, severe mechanical loading, gas transfer defects, malnutrition,
electrolyte disorders, and/or acid/base imbalances.
Aim of the study: To study effect of Hemodialysis on pulmonary function in patients
with end stage renal disease.
Materials and methods: The present study was conducted at Department of Medicine,
D. Y. Patil Hospital, Kolhapur, Maharashtra.We sampled all the hemodialysis patients
from four selected units that met the inclusion and exclusion criteria.
Results: A prospective observational study was conducted at Department of Medicine,
D. Y. Patil hospital, Kolhapur. Total 103 study subjects were selected for study who
were undergoing regular hemodialysis in current institution. Male study subjects were
53 (51.46%) while females were 50 (48.54%). Among study subjects 103 subjects, 57
(55.34%) in stage IV followed by 46 (44.66%) were in stage V. Out of 103 subjects, 46
(44.66%) were doing hemodialysis since last 1 to 3 years followed by 41 (39.81%) of
subjects doing hemodialysis for previous 6 to 12 month. Conclusion: According to our
findings, it can be concluded that patients with ESRD who receive hemodialysis may
have a better pulmonary function after dialysis sessions, which is significant for FVC,
FEV1, FEV1/ FVC ratio and PEFR.

Serum Renalase and its Relation to Left Ventricular Hypertrophy in Patients on Hemodialysis

Samar Gomaa Gamal, Adel Abd ElMohsen Ghorab, Islam Ali Elsayed, Said M Al-Barshomy,Nader Mohammad Mustafa

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 4, Pages 857-871

Background: Renalase is a blood-secreted protein produced only by the kidney; its
blood level approximately 3–5 μg/ml. The Left ventricular hypertrophy (LVH) is
defined by an augmented left ventricular mass that may be measured via
echocardiography or magnetic resonance imaging (MRI). The aim of the present
study was to study whether Renalase is a marker or has a potential role in
developing myocardial hypertrophy in CKD patients under hemodialysis (HD)
treatment.
Patients and methods: To achieve this target, 90 patients on maintenance HD were
incorporated in the present study.
Results: The mean renalase levels were 61.7±67.5 ng/mL in HD patients. The cutoff
value of Renalase was >57.9 ng/ml with a sensitivity of 92.3% and a Specificity of
84.0%. The mean LVMI of the studied dialysis patients was 138 g/m2. The majority
of cases were severely abnormal (60%). There was a statistically significant
difference between the age groups and the LVMI among dialysis patients. The level
of Renalase was significantly increased with the moderately and severely abnormal
LVMI among dialysis patients. The present study disclosed statistically significant
relations between the duration of dialysis and Renalase, HDL, CRP, and LVMI.
There were significant relations between the serum renalase and s. creat, bl. Urea,
Ph, LVMI and dialysis vintage. Also, there were significant positive relations
between LVMI and Hb, CRP, and dialysis vintage.
Conclusion: Renalase could be a novel predictive biomarker in the assessment of
LVH, which is closely associated with the increased risk of death in HD patients.